Who are PRIVIGEN (CSL Behring)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): IgPro, Asceniv™, Gammaplex (5%), Flebogamma 5% DIF, IRX-101, IGIV-C 10%.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/privigen-csl-behring.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

PRIVIGEN (CSL Behring) — Competitive Intelligence Brief

PRIVIGEN (CSL Behring) (PRIVIGEN (CSL Behring)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Intravenous immunoglobulin (IVIg). Area: Immunology.

marketed Intravenous immunoglobulin (IVIg) Fc receptors, complement system, pathogenic antigens and antibodies Immunology Small molecule Live · refreshed every 30 min

Target snapshot

PRIVIGEN (CSL Behring) (PRIVIGEN (CSL Behring)) — Hospices Civils de Lyon. PRIVIGEN is an intravenous immunoglobulin (IVIg) that provides passive immunity by supplying pooled human antibodies to modulate immune responses and replace deficient immunoglobulins.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
PRIVIGEN (CSL Behring) TARGET	PRIVIGEN (CSL Behring)	Hospices Civils de Lyon	marketed	Intravenous immunoglobulin (IVIg)	Fc receptors, complement system, pathogenic antigens and antibodies
IgPro	IgPro	CSL Behring	marketed	Intravenous immunoglobulin (IVIG)	Multiple pathogenic antigens (polyvalent)
Asceniv™	Asceniv™	ADMA Biologics, Inc.	marketed	Intravenous immunoglobulin (IVIG)	Polyclonal immunoglobulins (IgG)
Gammaplex (5%)	Gammaplex (5%)	Bio Products Laboratory	marketed	Intravenous immunoglobulin (IVIG)	Fc receptors and complement system (indirect mechanism via antibody delivery)
Flebogamma 5% DIF	Flebogamma 5% DIF	Instituto Grifols, S.A.	marketed	Intravenous immunoglobulin (IVIG)	Fc receptors, pathogenic antigens and antibodies
IRX-101	IRX-101	iRenix Medical, Inc.	phase 3	Intravenous immunoglobulin (IVIG)	Fc receptors, complement system
IGIV-C 10%	IGIV-C 10%	Grifols Therapeutics LLC	phase 3	Intravenous immunoglobulin (IVIG)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Intravenous immunoglobulin (IVIg) class)

Hospices Civils de Lyon · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). PRIVIGEN (CSL Behring) — Competitive Intelligence Brief. https://druglandscape.com/ci/privigen-csl-behring. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab